Evidence map›Paper›PMID 41674358›Full record

ArticleChembiochem : a European journal of chemical biology2026

CD44-Binding Peptide-Functionalized Antibiofouling Polymer Surface for High-Performance Separation of Human Mesenchymal Stromal Cells.

Moe Kato, Tadashi Nakaji-Hirabayashi, Kazuaki Matsumura, Chiaki Yoshikawa, Yuki Usui, Takahiro Kishioka, Taito Nishino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Moe KatoGraduate School of Innovative Life Science, University of Toyama, Toyama, Japan.
Tadashi Nakaji-HirabayashiGraduate School of Innovative Life Science, University of Toyama, Toyama, Japan.ORCID https://orcid.org/0000-0002-7562-3419
Kazuaki MatsumuraSchool of Materials Science, Japan Advanced Institute of Science and Technology, Nomi, Japan.
Chiaki YoshikawaResearch Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), Tsukuba, Japan.
Yuki UsuiMaterials Research Laboratories, Nissan Chemical Corporation, Toyama, Japan.
Takahiro KishiokaMaterials Research Laboratories, Nissan Chemical Corporation, Toyama, Japan.
Taito NishinoBiological Research Laboratories, Nissan Chemical Corporation, Shiraoka, Japan.

Funding

Grant-in-Aid for Scientific Research 15H05353Grant-in-Aid for Scientific Research 17KK0130Grant-in-Aid for Scientific Research 18K19907Grant-in-Aid for Scientific Research 22H3951Japan Society for the Promotion of ScienceJST SPRING JPMJSP2145
6 · The paper itself

Abstract

Cell transplantation therapy is a promising strategy for next-generation regenerative medicine. However, its clinical application is limited by the absence of safe and label-free methods for obtaining pure populations of functional cells. This study reports a peptide-functionalized zwitterionic polymer system designed for the selective and noninvasive isolation of human mesenchymal stem cells (hMSCs) from heterogeneous cell populations. The substrate was modified with poly(CMBMAm-co-PGMAn-co-MPTMS1) (PC

Indexed as

BiofoulingCell SeparationHyaluronan ReceptorsMesenchymal Stem CellsPeptidesPolymersCell DifferentiationCell ProliferationHumansSurface PropertiesCD44 protein, humanHyaluronan ReceptorsPeptidesPolymersantifouling surfacecell separationhuman mesenchymal stem celllabel‐free purificationpeptide‐functionalized polymerregenerative medicinezwitterionic polymer

Identifiers

PMID41674358
PMCPMC12895219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.